AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

AC Immune S.A.NASDAQ: ACIU

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns positive

Q1 FY2026 Accumulated OCI was CHF 7K, compared with -CHF 1K a year earlier. Over 3 fiscal years it compounded at -11.2% a year.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +800.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 7K-0.1% QoQ
Last fiscal yearDec 2025
CHF 7.01K+240.1% YoY
Year agoMar 2025
-CHF 1K+800.0% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+800.0%——
1 year+240.1%——
3-year CAGR-11.2%——
5-year CAGR——
10-year CAGR——

Accumulated OCI history

CHF · from the balance sheet

Latest · FY2025
7.01K CHF
Year-over-year change
+240.1%
4-year CAGR
+67681.7%

Accumulated OCI vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +800.0% is the highest of 9, against a peer median of -53.6%.
  • Accumulated OCI amounts to 0.0% of total assets for ACIU, versus a peer median of 0.0%.
ACIU Competitors
Accumulated OCI for ACIU and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANROAlto Neuroscience, Inc.Mar 2026$13K USD-7.1%—0.0%
ACIUAC Immune S.A.Mar 2026CHF 7K CHF+800.0%-11.2%0.0%
DRTSAlpha Tau Medical Ltd.Mar 2026$0 USD——0.0%
AMRNAmarin Corporation plcMar 2026$0 USD——0.0%
ALDXAldeyra Therapeutics, Inc.Mar 2026$0 USD-100.0%—0.0%
LYELLyell Immunopharma, Inc.Mar 2026-$9K USD-105.7%—0.0%
ANNXAnnexon, Inc.Mar 2026-$81K USD+11.0%—0.0%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026-$253K USD-248.8%—0.1%
SLNSilence Therapeutics plcMar 2026-$3.37M USD-141.7%—2.9%
MREOMereo BioPharma Group plcMar 2026-$12.57M USD+17.8%—31.0%
CLLSCellectis S.A.Mar 2026-$33.2M USD+10.9%—11.5%
Peer median (excluding ACIU) —-53.6%—0.0%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents82.22M31.59M78.49M36.28M26.83M
Short-term Investments116M91M24.55M129.21M64.69M
Net Receivables975K408K15.05M1.1M681.77K
Inventory00000
Other Current Assets428K392K622K1.1M0
Total Current Assets202.63M128.09M125.15M171.99M96.83M
Property, Plant & Equipment (Net)8.03M7.07M6.88M8.09M6.54M
Goodwill00000
Intangible Assets50.42M50.42M50.42M50.42M50.47M
Long-term Investments00361K0584.66K
Tax Assets00000
Other Non-current Assets363K361K0415K0
Total Non-current Assets58.81M57.84M57.66M58.92M57.59M
Total Assets261.44M185.94M182.81M230.91M154.43M
Account Payables2M929K1.68M2.66M2.07M
Short-term Debt0000852.97K
Tax Payables00000
Deferred Revenue00138K083.8M
Other Current Liabilities717K587K085.06M3.83M
Total Current Liabilities20.03M11.48M13.58M100.84M94.8M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00002.34M
Other Non-current Liabilities7.1M3.21M5.77M13.4M8.66M
Total Non-current Liabilities9.44M5.47M8.6M17.81M14.69M
Total Liabilities29.46M16.95M22.17M118.64M109.49M
Common Stock1.79M1.8M2.09M2.23M2.26M
Retained Earnings(200.94M)(264.02M)(316.2M)(368.24M)(439.52M)
Accumulated OCI010K(51K)(5K)7.01K
Other Stockholders Equity(0)(0)(0)00
Minority Interest00000
Total Equity231.98M168.99M160.64M112.27M44.93M
Total Debt2.91M2.8M3.5M5.43M4.55M
Net Debt(79.31M)(28.79M)(75M)(30.85M)(22.28M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.